



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: November 19, 2021

Administrative Circular: 2021:46

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- 'Pediatric populations – 5 to 11 years of age (inclusive)' has been added.

Please remove page numbers: 1-2 dated November 15, 2021

Please add new page numbers: 1-2 dated November 19, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Adult/Adolescent)

- The product name has been updated to differentiate from the pediatric formulation.
- Doses and Schedules: Footnote A has been revised to indicate that the minimum age for vaccine receipt is based on age at presentation (i.e., the Pfizer COVID-19 vaccine adult/adolescent formulation may be offered to individuals on or after their 12th birthday).

Please remove page numbers: 1-6 dated November 12, 2021

Please add new page numbers: 1-6 dated November 19, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Pediatric)

- This new product page has been added.

Please add new page numbers: 1-5 dated November 19, 2021

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

Please remove page numbers: 1-4 dated November 12, 2021

Please add new page numbers: 1-4 dated November 19, 2021

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

Please remove page numbers: 1-4 dated November 12, 2021

Please add new page numbers: 1-4 dated November 19, 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated November 2021 and replace with the enclosed updated Title Page and Table of Contents dated November 19, 2021.

Supporting resources:

Guidance Document on the Management of Inadvertent Vaccine Errors

Content has been added to address the management of potential inadvertent vaccine errors related to booster doses, as well as the Pfizer-BioNTech COVID-19 Vaccine Pediatric formulation (10 mcg).

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division